{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:54:36Z","timestamp":1790189676403,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81925006"],"award-info":[{"award-number":["81925006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2024-1-4073"],"award-info":[{"award-number":["2024-1-4073"]}]},{"name":"National Key Research and Development Program of China","award":["2024YFC2511000"],"award-info":[{"award-number":["2024YFC2511000"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,9]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Proteinuria responses to endothelin receptor antagonists and sodium-glucose cotransporter 2 inhibitors were not correlated.<\/jats:p>\n <\/jats:list-item>\n \n Ambrisentan-henagliflozin combination therapy reduced proteinuria similarly to ambrisentan monotherapy but exceeded henagliflozin alone.<\/jats:p>\n <\/jats:list-item>\n \n Combination therapy resulted in markedly less fluid retention and weight gain compared with endothelin receptor antagonist monotherapy.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Sodium-glucose cotransporter 2 (SGLT2) inhibitors and endothelin receptor antagonists (ERAs) can reduce proteinuria and may slow kidney progression in IgA nephropathy. Their potential synergistic efficacy and safety are unclear.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This open-label randomized crossover trial enrolled adults with IgA nephropathy, eGFR >30 ml\/min per 1.73 m\n 2<\/jats:sup>\n , and 24-hour urine protein-creatinine ratio (UPCR) \u22650.44 g\/g or 24-hour urine protein \u22650.5 g, despite maximal renin-angiotensin system blockade. Treatments were given in random order (ambrisentan 5 mg\/d, henagliflozin 10 mg\/d, and combination), each for 4 weeks followed by a 4-week washout. Primary end point was correlation between treatments in 24-hour UPCR changes. Secondary end points included eGFR change. Safety end points included fluid retention (body weight change).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Sixty-five patients were enrolled, with a mean baseline eGFR of 69 ml\/min per 1.73 m\n 2<\/jats:sup>\n (SD=23) and a median 24-hour UPCR of 0.8 g\/g (0.6\u20131.3). No correlation was found in 24-hour UPCR reduction between single-agent therapy and combination therapy (ambrisentan,\n r<\/jats:italic>\n =0.13,\n P<\/jats:italic>\n = 0.97; henagliflozin,\n r<\/jats:italic>\n =0.04,\n P<\/jats:italic>\n = 1.00). After treatment, the mean reduction in 24-hour UPCR was \u221244% with combination therapy (95% confidence interval [CI], \u221252 to \u221234), which was similar to ambrisentan alone (\u221248%; 95% CI, \u221256 to \u221239) but significantly superior to henagliflozin alone (\u221221%; 95% CI, \u221233 to \u22126). The mean reduction in eGFR from baseline was \u22124.7 ml\/min per 1.73 m\n 2<\/jats:sup>\n (95% CI, \u22126.9 to \u22122.6) with combination therapy, which was significantly greater than with ambrisentan (\u22120.5 ml\/min per 1.73 m\n 2<\/jats:sup>\n ; 95% CI, \u22122.8 to 1.9) but comparable with henagliflozin (\u22123.5 ml\/min per 1.73 m\n 2<\/jats:sup>\n ; 95% CI, \u22125.8 to \u22121.2). Less fluid retention occurred with combination treatment versus ambrisentan alone.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Combining an ERA with an SGLT2 inhibitor further reduced proteinuria versus SGLT2 inhibitor alone, with less fluid retention than ERA alone.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n Chinese Clinical Trial Registry (ChiCTR2400080435).<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000001097","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:00:39Z","timestamp":1775664039000},"page":"2016-2026","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy"],"prefix":"10.1681","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1047-1589","authenticated-orcid":false,"given":"Qinlan","family":"Chen","sequence":"first","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Chen","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-6956","authenticated-orcid":false,"given":"Lijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-7054","authenticated-orcid":false,"given":"Sufang","family":"Shi","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-707X","authenticated-orcid":false,"given":"Xujie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4490-1543","authenticated-orcid":false,"given":"Hongyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-1209","authenticated-orcid":false,"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-9651","authenticated-orcid":false,"given":"Ling","family":"Guo","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Statistics Division, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0128-8408","authenticated-orcid":false,"given":"Jinwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Bao","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3857-2253","authenticated-orcid":false,"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"},{"name":"The Second People's Hospital of Shanxi Province, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Ning","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"},{"name":"Department of Nephrology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2648-9793","authenticated-orcid":false,"given":"Yuting","family":"Cai","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"},{"name":"Renal Division, Zhangzhou Municipal Hospital of Fujian Province, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"He","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"},{"name":"Department of Nephrology, NHC Key Laboratory of Pulmonary Immunological Disease, Guizhou Provincial Key Laboratory of Pathogenesis and Prevention of Common Chronic Diseases Research, Guizhou Provincial People's Hospital, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Liu","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"},{"name":"Department of Nephrology, Zibo Central Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2883-4636","authenticated-orcid":false,"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"},{"name":"Department of Nephrology, Affiliated Hospital of Hebei University, Baoding, Hebei, China"},{"name":"Key Laboratory of Bone Metabolism and Physiology in Chronic Kidney Disease of Hebei Province, Baoding, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Lv","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9855-4068","authenticated-orcid":false,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Renal Division, Key Laboratory of Renal Disease, Peking University First Hospital, Peking University Institute of Nephrology, Ministry of Health of China, Ministry of Education, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"3","key":"B1-20260901","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis."},{"issue":"12","key":"B2-20260901","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B3-20260901","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B4-20260901","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int."},{"issue":"4S","key":"B5-20260901","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 Clinical Practice Guideline for the management of Immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int."},{"issue":"5","key":"B6-20260901","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"issue":"10417","key":"B7-20260901","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet."},{"issue":"6","key":"B8-20260901","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med."},{"issue":"1","key":"B9-20260901","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"issue":"2","key":"B10-20260901","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B11-20260901","doi-asserted-by":"crossref","first-page":"sfae394","DOI":"10.1093\/ckj\/sfae394","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"18","author":"Schanz","year":"2025","journal-title":"Clin kidney J."},{"issue":"10416","key":"B12-20260901","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet."},{"issue":"15","key":"B13-20260901","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2165\/00003495-200868150-00008","article-title":"Ambrisentan","volume":"68","author":"Croxtall","year":"2008","journal-title":"Drugs."},{"issue":"10","key":"B14-20260901","first-page":"741","article-title":"Efficacy and safety analysis of ambrisentan treatment for IgA nephropathy","volume":"23","author":"Li","year":"2024","journal-title":"Chin J Blood Purif"},{"issue":"11","key":"B15-20260901","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/jdi.14306","article-title":"Sodium-glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes","volume":"15","author":"Zhang","year":"2024","journal-title":"J Diabetes Investig."},{"issue":"4","key":"B17-20260901","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.0000000538","article-title":"The selective endothelin receptor antagonist SC0062 in IgA nephropathy","volume":"36","author":"Heerspink","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B18-20260901","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B19-20260901","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"B20-20260901","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull."},{"issue":"7","key":"B22-20260901","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"B23-20260901","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"B24-20260901","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B25-20260901","doi-asserted-by":"crossref","first-page":"sfaf066","DOI":"10.1093\/ckj\/sfaf066","article-title":"Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis","volume":"18","author":"Tian","year":"2025","journal-title":"Clin kidney J."},{"issue":"3","key":"B26-20260901","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat Rev Nephrol."},{"issue":"9","key":"B27-20260901","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/ndt\/gfae021","article-title":"Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy","volume":"39","author":"Nagasawa","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B28-20260901","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med."},{"issue":"10388","key":"B29-20260901","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet."},{"issue":"4","key":"B30-20260901","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"issue":"9","key":"B31-20260901","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose\u2010regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab."},{"issue":"13","key":"B32-20260901","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40265-021-01573-3","article-title":"A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease","volume":"81","author":"Del Vecchio","year":"2021","journal-title":"Drugs."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:00:37Z","timestamp":1788282037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001097"}},"subtitle":["A Randomized Crossover Trial"],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000001097","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"2025-10-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}